Publications du centre

Liste des publications

Publications du département d'ophtalmologie

Bienvenue sur la page dédiée aux publications scientifiques du département d'ophtalmologie du centre médical des Aravis. Notre équipe médicale s'investit activement dans la recherche et l'innovation afin d'améliorer constamment la prise en charge de nos patients. Nos travaux portent sur un large éventail de thématiques, notamment :

Domaines d'expertise

Les maladies de la cornée, telles que le kératocône, et les techniques chirurgicales associées (greffe de cornée, etc.).
Les pathologies rétiniennes, comme la DMLA ou le décollement de la rétine, avec une expertise particulière dans les traitements par injections intravitréennes et la chirurgie vitréo-rétinienne.
L'épidémiologie et la santé publique en ophtalmologie, en utilisant des bases de données nationales pour analyser les tendances et les facteurs de risque de différentes maladies oculaires.
L'impact des technologies numériques sur la santé oculaire, notamment l'utilisation de la télémédecine pour le dépistage de la rétinopathie diabétique.

Nous sommes fiers de partager ici nos contributions à l'avancement des connaissances en ophtalmologie. N'hésitez pas à consulter nos publications pour en savoir plus sur nos domaines d'expertise et nos recherches en cours.

Afficher tous

2022

Ghezala, Inès Ben; Mariet, Anne-Sophie; Benzenine, Eric; Bardou, Marc; Bron, Alain Marie; Gabrielle, Pierre-Henry; Baudin, Florian; Quantin, Catherine; Creuzot-Garcher, Catherine

Association between obstetric complications and intravitreal anti-vascular endothelial growth factor agents or intravitreal corticosteroids Article de journal

Dans: J. Pers. Med., vol. 12, no. 9, p. 1374, 2022.

Résumé | BibTeX | Étiquettes: anti-vascular endothelial growth factor; corticosteroid; drug safety; intravitreal injection; obstetric complication; pharmacoepidemiology; pregnancy

@article{Ben_Ghezala2022-ir,

title = {Association between obstetric complications and intravitreal 

 anti-vascular endothelial growth factor agents or intravitreal 

 corticosteroids},

author = {Inès Ben Ghezala and Anne-Sophie Mariet and Eric Benzenine and Marc Bardou and Alain Marie Bron and Pierre-Henry Gabrielle and Florian Baudin and Catherine Quantin and Catherine Creuzot-Garcher},

year  = {2022},

date = {2022-08-01},

journal = {J. Pers. Med.},

volume = {12},

number = {9},

pages = {1374},

publisher = {MDPI AG},

abstract = {This nationwide population-based cohort study aimed to describe 

 the use of intravitreal injections (IVTs) of anti-vascular 

 endothelial growth factor (anti-VEGF) agents and corticosteroids 

 in pregnant women in France and to report on the incidence of 

 obstetric and neonatal complications. All pregnant women in 

 France who received any anti-VEGF or corticosteroid IVT during 

 pregnancy or in the month preceding pregnancy from 1 January 

 2009 to 31 December 2018 were identified in the national 

 medico-administrative databases. Between 2009 and 2018, there 

 were 5,672,921 IVTs performed in France. Among these IVTs, 228 

 anti-VEGF or corticosteroid IVTs were administered to 139 women 

 during their pregnancy or in the month preceding their 

 pregnancy. Spontaneous abortion or the medical termination of 

 pregnancy occurred in 10 women (16.1%) who received anti-VEGF 

 agents and in one (3.1%) of the women who received corticosteroids (p = 0.09). This is the first national cohort 

 study of pregnant women treated with anti-VEGF or corticosteroid 

 IVTs. We found a high incidence of obstetric complications in 

 pregnant women treated with anti-VEGF or corticosteroid IVTs but 

 could not demonstrate a statistically significant association 

 between the intravitreal agents and these complications. These 

 agents should continue to be used with great caution in pregnant 

 women.},

keywords = {anti-vascular endothelial growth factor; corticosteroid; drug   safety; intravitreal injection; obstetric complication;   pharmacoepidemiology; pregnancy},

pubstate = {published},

tppubtype = {article}

}

Fermer

Explorer

Recherche

Ghezala, Inès Ben; Mariet, Anne-Sophie; Benzenine, Eric; Bardou, Marc; Bron, Alain Marie; Gabrielle, Pierre-Henry; Baudin, Florian; Quantin, Catherine; Creuzot-Garcher, Catherine

Association between obstetric complications and intravitreal anti-vascular endothelial growth factor agents or intravitreal corticosteroids Article de journal

Dans: J. Pers. Med., vol. 12, no. 9, p. 1374, 2022.

Résumé | BibTeX

@article{Ben_Ghezala2022-ir,

title = {Association between obstetric complications and intravitreal 

 anti-vascular endothelial growth factor agents or intravitreal 

 corticosteroids},

author = {Inès Ben Ghezala and Anne-Sophie Mariet and Eric Benzenine and Marc Bardou and Alain Marie Bron and Pierre-Henry Gabrielle and Florian Baudin and Catherine Quantin and Catherine Creuzot-Garcher},

year  = {2022},

date = {2022-08-01},

journal = {J. Pers. Med.},

volume = {12},

number = {9},

pages = {1374},

publisher = {MDPI AG},

abstract = {This nationwide population-based cohort study aimed to describe 

 the use of intravitreal injections (IVTs) of anti-vascular 

 endothelial growth factor (anti-VEGF) agents and corticosteroids 

 in pregnant women in France and to report on the incidence of 

 obstetric and neonatal complications. All pregnant women in 

 France who received any anti-VEGF or corticosteroid IVT during 

 pregnancy or in the month preceding pregnancy from 1 January 

 2009 to 31 December 2018 were identified in the national 

 medico-administrative databases. Between 2009 and 2018, there 

 were 5,672,921 IVTs performed in France. Among these IVTs, 228 

 anti-VEGF or corticosteroid IVTs were administered to 139 women 

 during their pregnancy or in the month preceding their 

 pregnancy. Spontaneous abortion or the medical termination of 

 pregnancy occurred in 10 women (16.1%) who received anti-VEGF 

 agents and in one (3.1%) of the women who received corticosteroids (p = 0.09). This is the first national cohort 

 study of pregnant women treated with anti-VEGF or corticosteroid 

 IVTs. We found a high incidence of obstetric complications in 

 pregnant women treated with anti-VEGF or corticosteroid IVTs but 

 could not demonstrate a statistically significant association 

 between the intravitreal agents and these complications. These 

 agents should continue to be used with great caution in pregnant 

 women.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

Fermer